There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kura Oncology (KURA – Research Report), Gossamer Bio (GOSS – Research Report) and 4D Molecular Therapeutics (FDMT – Research Report) with bullish sentiments.
Kura Oncology (KURA)
Stifel Nicolaus analyst Bradley Canino maintained a Buy rating on Kura Oncology today and set a price target of $24.00. The company’s shares closed last Wednesday at $15.06, close to its 52-week high of $15.49.
According to TipRanks.com, Canino is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kura Oncology with a $28.32 average price target, which is an 83.2% upside from current levels. In a report issued on December 22, Mizuho Securities also initiated coverage with a Buy rating on the stock with a $26.00 price target.
See the top stocks recommended by analysts >>
Gossamer Bio (GOSS)
In a report released today, Yasmeen Rahimi from Piper Sandler assigned a Buy rating to Gossamer Bio, with a price target of $15.00. The company’s shares closed last Wednesday at $1.00.
According to TipRanks.com, Rahimi is a 4-star analyst with an average return of
Currently, the analyst consensus on Gossamer Bio is a Strong Buy with an average price target of $6.63.
4D Molecular Therapeutics (FDMT)
BMO Capital analyst Kostas Biliouris maintained a Buy rating on 4D Molecular Therapeutics yesterday and set a price target of $50.00. The company’s shares closed last Wednesday at $20.17.
According to TipRanks.com, Biliouris is a 3-star analyst with an average return of
Currently, the analyst consensus on 4D Molecular Therapeutics is a Strong Buy with an average price target of $33.17.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on KURA:
- Nike downgraded, Waste Management upgraded: Wall Street’s top analyst calls
- Kura Oncology initiated with a Buy at Mizuho
- Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call
- Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial
- Kura Oncology announces clinical collaboration to evaluate ziftomenib
